Charles Schwab Investment Management Inc Cardiff Oncology, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 121,293 shares of CRDF stock, worth $308,084. This represents 0.0% of its overall portfolio holdings.
Number of Shares
121,293
Previous 108,790
11.49%
Holding current value
$308,084
Previous $241,000
34.02%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CRDF
# of Institutions
90Shares Held
12.3MCall Options Held
813KPut Options Held
91.1K-
Black Rock Inc. New York, NY2.63MShares$6.68 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$5.52 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA928KShares$2.36 Million0.0% of portfolio
-
State Street Corp Boston, MA833KShares$2.11 Million0.0% of portfolio
-
Mai Capital Management663KShares$1.68 Million0.02% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $110M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...